¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder

Abstract

The aim of the present study was to investigate the role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in the diagnosis of post-transplant lymphoproliferative disorder (PTLD), a serious complication of solid organ and bone marrow transplant. Between January 2004 and January 2012, 40 patients (22 males; median age 52 ± 17.4 years, range 11–77 years) underwent ¹⁸F-FDG PET/CT scans in our department for diagnostic evaluation of PTLD. Twenty-three (57.5%) patients had negative ¹⁸F-FDG PET/CT and 17 (42.5%) had a positive examination. In five patients PET/CT revealed extranodal disease (adrenal, pleural, spleen, liver, lung, esophagus and bone involvement). On the basis of our results, ¹⁸F-FDG PET/CT had a sensitivity of 88.2% (95% confidence interval [CI] 0.62–0.98), a specificity of 91.3% (CI 0.70–0.98), a positive predictive value of 88.2% (CI 0.62–0.98) and a negative predictive value of 91.3% (CI 0.70–0.98). The diagnostic performance of CT in patient-based analysis was: a sensitivity of 87.5% (CI 0.60–0.97), a specificity of 88.8% (CI 0.64-0.98), a positive predictive value of 87.5% (CI 0.60–0.97) and a negative predictive value of 88.8% (CI 0.64–0.98). PET/CT in five cases revealed more findings than CT, upstaging the disease, and revealed three extranodal findings, not visualized in conventional imaging. ¹⁸F-FDG PET/CT plays a significant role in the setting of PTLD diagnosis, demonstrating its high accuracy in detecting PTLD.

Keywords::

• ¹⁸F-FDG PET/CT
• post-transplant lymphoproliferative disorder
• diagnosis
• treatment alteration

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.